AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7742841
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment on precooled tissue (preceded by 5 minutes of ice)
Trial: 7742841
Drug: Ultrasound with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound with no preceding treatment
Trial: 2258042
Drug: Chlorpheniramine (antihistamine)
RxNorm normalized name: Ahist Antihistamine
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine (antihistamine)
Trial: 2258042
Drug: Placebo (cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cherry syrup)
Trial: 25650051
Drug: 340 mg
RxNorm normalized name: febantel 340 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 340 mg ADS‐5102
Trial: 25650051
Drug: 260 mg
RxNorm normalized name: aspirin 260 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 260 mg ADS‐5102
Trial: 25650051
Drug: 420 mg
RxNorm normalized name: choline 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420 mg ADS‐5102
Trial: 9108813
Drug: Paroxetine 20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20-40 mg/day
Trial: 12096198
Drug: Inhaled methacholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methacholine (MCh) after allergen challenge
Trial: 12096198
Drug: Inhaled cysteinyl
RxNorm normalized name: bis(cysteinyl maleimide) PEG 20000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled cysteinyl leukotriene D(4) (LTD(4)) after allergen challenge
Trial: 12096198
Drug: Inhaled methacholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methacholine (MCh) after control
Trial: 12096198
Drug: Inhaled cysteinyl
RxNorm normalized name: bis(cysteinyl maleimide) PEG 20000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled cysteinyl leukotriene D(4) (LTD(4)) after control
Trial: 12096198
Drug: Inhaled cysteinyl
RxNorm normalized name: bis(cysteinyl maleimide) PEG 20000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled cysteinyl leukotriene D(4) (LTD(4)) challenge reproducibility
Trial: 10492062
Drug: Dipyrone 500
RxNorm normalized name: dipyrone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 500 mg t.i.d.
Trial: 8609254
Drug: Topical calcipotriene
RxNorm normalized name: calcipotriene Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcipotriene ointment (50 microgram/gm, maximum usage, 120 gm per week) for 8 weeks
Trial: 27600789
Drug: Mechanical debridement
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical debridement with adjunct antimicrobial photodynamic therapy (aPDT)
Trial: 25877666
Drug: Terconazole vaginal
RxNorm normalized name: terconazole Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terconazole vaginal suppository (80 mg for 6 days)
Trial: 25877666
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole (150 mg, two doses)
Trial: 23704676
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus rosiglitazone (M + R)
Trial: 23704676
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus lifestyle program (M + L)
Trial: 25885385
Drug: Ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.3 mg iv
Trial: 25885385
Drug: Palonosetron 0.075
RxNorm normalized name: palonosetron 0.075 MG in 1.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.075 mg iv
Trial: 25885385
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg iv
Trial: 17526178
Drug: Compound E‐Bei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound E‐Bei ointment (CEBO)
Trial: 10527993
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone (i.m. progesterone-in-oil preparation)
Trial: 8750402
Drug: Aspirin 3900
RxNorm normalized name: aspirin 3900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 3900 mg/d
Trial: 8750402
Drug: Bromfenac sodium
RxNorm normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac sodium 300 mg/d
Trial: 1777605
Drug: Late intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late intensification therapy (LIT) with high-dose methotrexate (HD-MTX) administered at 2,000 mg/m2 per dose per week, given by 24 h infusion, three doses every 12 weeks.
Trial: 26832746
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 (Daily dosing)
Trial: 26832746
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 (Weekly dosing)
Trial: 26832746
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 (Biweekly dosing)
Trial: 24903522
Drug: Rocuronium (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (0.2 mg/kg)
Trial: 9818934
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (plasma exchange and intravenous immunoglobulin)
Trial: 7648483
Drug: 100 IU
RxNorm normalized name: Vitamin E 100 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU salmon calcitonin (5 suppositories per week)
Trial: 7648483
Drug: 200 IU
RxNorm normalized name: Vitamin E 200 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU salmon calcitonin (3 suppositories per week)
Trial: 7648483
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 suppositories per week)
Trial: 7648483
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups received 500 mg/day of calcium supplementation
Trial: 1273220
Drug: Butobarbitone 100
RxNorm normalized name: butobarbitone 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butobarbitone 100 mg
Trial: 1273220
Drug: Butobarbitone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butobarbitone 200 mg
Trial: 1273220
Drug: Lactose dummy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose dummy treatment
Trial: 27451467
Drug: Electronic alert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic alert system for OAC prescription
Trial: 24482066
Drug: Levofloxacin, 500
RxNorm normalized name: LevoFLOXacin, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin, 500 mg daily for 30 days
Trial: 22508814
Drug: Accelerated radiotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiotherapy plus carbogen inhalation and nicotinamide (ARCON)
Trial: 22508814
Drug: Accelerated radiotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiotherapy plus carbogen inhalation and nicotinamide (ARCON) in patients with hypoxic tumors
Trial: 17916109
Drug: Lubiprostone 24
RxNorm normalized name: LUBIPROSTONE 24MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone 24 mcg twice daily for 4 weeks
Trial: 15777101
Drug: Erdosteine suspension
RxNorm normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine suspension 175mg/5mL twice daily for 1 month
Trial: 10495375
Drug: Finasteride 0.2
RxNorm normalized name: MINOXIDIL 5 g in 100 g / FINASTERIDE 0.25 g in 100 g TOPICAL AEROSOL, FOAM [JOHNSON FOAM PRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 0.2 mg/day
Trial: 10495375
Drug: Finasteride 0.01
RxNorm normalized name: ALFATRADIOL 0.05 g in 100 g / MINOXIDIL SULFATE ESTER 12 g in 100 g / FINASTERIDE 0.01 g in 100 g TOPICAL LIQUID [NR-11]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 0.01 mg/day
Trial: 2006245
Drug: Intramuscular scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular scopolamine (0.3 mg, 0.6 mg)
Trial: 6643396
Drug: Oral lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lorazepam (2 mg)
Trial: 27832140
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CAS and HD-tDCS
Trial: 10858333
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin followed by oral azithromycin
Trial: 9347429
Drug: Intravenous patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient‐controlled analgesia with morphine (1.0 mg dose, 6 minute lock‐out interval)
Trial: 3764625
Drug: Paromomycin (25-35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin (25-35 mg/kg daily in three divided doses for seven days)
Trial: 12100776
Drug: Valdecoxib 20
RxNorm normalized name: valdecoxib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 20 mg
Trial: 12209034
Drug: Valdecoxib 40
RxNorm normalized name: valdecoxib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 40 mg
Trial: 12700612
Drug: Soy-based meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy-based meal replacement (240 g/day, 1200 kcal/day)
Trial: 11092464
Drug: Pamidronate +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate + chemotherapy
Trial: 28961465
Drug: Pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 2 mg/kg
Trial: 28961465
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg
Trial: 26115796
Drug: Chemotherapy (investigator-choice)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator-choice)
Trial: 15892857
Drug: BB-10153 (0.08,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BB-10153 (0.08, 0.2, 0.6, 1.2, 1.8, 2.4, 3.6, 4.8 mg kg(‐1))
Trial: 12473883
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (fistulotomy)
Trial: 7657042
Drug: OME +
RxNorm normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OME + AMX (high-dose omeprazole 2 x 40 mg and amoxicillin 2 x 1,000 mg for 10 days)
Trial: 7657042
Drug: OME (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OME (high-dose omeprazole 2 x 40 mg)
Trial: 2760248
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (basic oral hygiene programme without chlorhexidine)
Trial: 27941110
Drug: Trained mothers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trained mothers (MUMs) providing rectal artesunate treatment
Trial: 27941110
Drug: Community-based health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based health workers (CHWs) providing rectal artesunate treatment
Trial: 27941110
Drug: Trained traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trained traditional healers (THs) providing rectal artesunate treatment
Trial: 27941110
Drug: Trained community-chosen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trained community-chosen personnel (COMs) providing rectal artesunate treatment
Trial: 20184444
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of tramadol
Trial: 22089326
Drug: 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg/kg of fentanyl
Trial: 9605644
Drug: Granulocyte colony‐stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony‐stimulating factor (G‐CSF)
Trial: 11520775
Drug: 3-course treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-course treatment (DAT 2 + 7)
Trial: 11520775
Drug: 6-course treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-course treatment (subsequent COAP, DAT 2 + 5, and COAP)
Trial: 11520775
Drug: 12-month maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12-month maintenance treatment with low-dose interferon
Trial: 10193281
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with ropivacaine 2.5 mg ml‐1
Trial: 10193281
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with bupivacaine 2.5 mg ml‐1
Trial: 7850820
Drug: Enoximone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (1 mg/kg)
Trial: 19719746
Drug: Digoxin (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.01 mg/kg)
Trial: 3182329
Drug: 5-FU administered
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU administered at a dose of 300 mg/m2 days 1-5 and 28-32 (Group A)
Trial: 3182329
Drug: 5-FU administered
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU administered at a dose of 300 mg/m2 days 1-3 and 28-31 (Group B)
Trial: 31573637
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C infusion (50 mg/kg in dextrose 5% in water, n=84)
Trial: 27410907
Drug: Atomoxetine (1.0‐1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (1.0‐1.4 mg/kg/day)
Trial: 26369655
Drug: Rebamipide 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide 0.1 g three times per day for 26 weeks
Trial: 16130875
Drug: Total‐etch, two‐step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total‐etch, two‐step bonding agent
Trial: 16130875
Drug: Self‐etch, two‐step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐etch, two‐step bonding agent
Trial: 16130875
Drug: Self‐etch, one‐step
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐etch, one‐step bonding agent
Trial: 12103366
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drug (NSAID, Naproxen sodium)
Trial: 9918478
Drug: Orlistat, 120
RxNorm normalized name: Orlistat, 120 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat, 120 mg 3 times a day
Trial: 9918478
Drug: Orlistat, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat, 60 mg
Trial: 8787955
Drug: Dexfenfluramine (DF)
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine (DF) 15 mg twice daily
Trial: 19803010
Drug: Ceftazidime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (1 to 6 g daily im or iv)
Trial: 19803010
Drug: Ceftazidime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (1 g im)
Trial: 19803010
Drug: Ceftazidime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (1 and 2 g im 12‐hourly)
Trial: 19803010
Drug: Ceftazidime (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (0.5 g 12‐hourly)
Trial: 29151416
Drug: Short-term deep
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term deep sedation (midazolam 0.1-0.2 mg/kg, RASS score -4 to -3, duration no more than 12 hours)
Trial: 19028780
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (MED), n = 1100
Trial: 16880785
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg twice daily (b.i.d.)
Trial: 11340825
Drug: Weekly teaching
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly teaching group (1 hour/week for 10 weeks)
Trial: 11340825
Drug: Intensive teaching
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive teaching group (2 hours daily for 5 days)
Trial: 7957152
Drug: BCAA infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCAA infusion (260 mg x kg‐1 x h‐1 for 70 min)
Trial: 3357367
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration before passive upright tilt
Trial: 29988969
Drug: internet‐based cognitive‐behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet‐based cognitive‐behavioural therapy (iCBT)
Trial: 29072476
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT) administration
Trial: 21558574
Drug: GliSODin extract
RxNorm normalized name: GliSODin
DrugBank: GliSODin (DB17013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GliSODin extract (500 mg, 2 capsules once daily for 6 weeks)
Trial: 17011760
Drug: Alprostadil (prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprostadil (prostaglandin E(1) analogue) administered during operation
Trial: 11550161
Drug: 0.15% benzydamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% benzydamine oral rinse, 15 mL for 2 minutes, 4-8 times daily before and during RT, and for 2 weeks after completion of RT.
Trial: 11550161
Drug: 0.15% benzydamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% benzydamine oral rinse
Trial: 11550161
Drug: Accelerated RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated RT doses (> or = 220 cGy/day)
Trial: 8271169
Drug: BSS (Balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSS (Balanced Salt Solution)
Trial: 3135572
Drug: Recombinant interferon-gamma
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon-gamma (50 micrograms daily for 20 days, then 50 micrograms every second day up to day 28, subcutaneous injection)
Trial: 25911881
Drug: HAIC (Hepatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAIC (Hepatic artery infusion chemotherapy) - 5‐FU 1000 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1, Gemcitabine 1000 mg/m2 on day 1 and 8, starting 3 weeks after operation with intervals of 4 weeks.
Trial: 23357657
Drug: Internet-delivered behavioral
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered behavioral activation combined with acceptance and commitment therapy (ACT) for 8 weeks
Trial: 15998467
Drug: Epidural blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blood patch (EDBP)
Trial: 8697552
Drug: Edrophonium 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.05 mg.kg‐1
Trial: 8697552
Drug: Edrophonium 0.1
RxNorm normalized name: atropine-edrophonium 0.14 mg-10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.1 mg.kg‐1
Trial: 8697552
Drug: Edrophonium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.5 mg.kg‐1
Trial: 8697552
Drug: Edrophonium 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1.0 mg.kg‐1
Trial: 8697552
Drug: Placebo (Edrophonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Edrophonium 0.0 mg.kg‐1)
Trial: 2003848
Drug: Medication communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication communication skills program
Trial: 2003848
Drug: Medication education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication education program
Trial: 6224928
Drug: Biofeedback-assisted relaxation
RxNorm normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biofeedback-assisted relaxation and cognitive imagery treatment
Trial: 28982774
Drug: Salmeterol 50 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 μg plus fluticasone propionate 500 μg
Trial: 28982774
Drug: Salmeterol 50 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 μg
Trial: 23653047
Drug: Voriconazole, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole, administered twice daily orally
Trial: 23653047
Drug: Intravenous voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous voriconazole
Trial: 9757157
Drug: Standard fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fixed-dose zidovudine (500 mg/day)